Azithromycin Should NOT Be Used as First-Line Treatment for Acute Sinusitis
Amoxicillin remains the first-line antibiotic for uncomplicated acute bacterial sinusitis in both adults and children. 1, 2 Azithromycin is explicitly discouraged due to documented resistance patterns.
Why Azithromycin Is Not Recommended
The most recent and authoritative pediatric guidelines 3 specifically state that surveillance studies have shown resistance of pneumococcus and Haemophilus influenzae to azithromycin, indicating that it should not be used to treat acute bacterial sinusitis in persons with penicillin hypersensitivity. This represents a critical shift from older practices.
The 2005 adult guidelines 1 list macrolides (including azithromycin) only as alternatives for patients allergic to or intolerant of amoxicillin—not as first-line therapy. Even in this context, cephalosporins and quinolones are mentioned alongside macrolides, suggesting they are not preferred alternatives.
First-Line Treatment Algorithm
For adults and children ≥2 years without risk factors:
- Amoxicillin 45 mg/kg/day divided twice daily for 10-14 days 1
- In communities with >10% penicillin-nonsusceptible S. pneumoniae, use high-dose amoxicillin 80-90 mg/kg/day (max 2g per dose) 2
For patients with risk factors (age <2 years, daycare attendance, recent antibiotic use within 30 days, moderate-to-severe illness):
- High-dose amoxicillin-clavulanate (80-90 mg/kg/day of amoxicillin component with 6.4 mg/kg/day clavulanate) divided twice daily 2
Reassess at 72 hours: If worsening or no improvement, switch antibiotics 2
When Azithromycin Might Be Considered (With Caveats)
The FDA label 4 does list acute bacterial sinusitis as an indication with dosing of 500 mg once daily for 3 days in adults and 10 mg/kg once daily for 3 days in children. However, this approval predates the resistance data cited in current guidelines.
Research studies 5, 6, 7 from the early 2000s showed azithromycin had comparable efficacy to amoxicillin-clavulanate or levofloxacin, with clinical cure rates of 88-98%. A 2025 meta-analysis 8 reported a 70.86% cure rate with azithromycin. However, these studies do not override current guideline recommendations based on resistance patterns.
Critical Pitfall to Avoid
Do not prescribe azithromycin simply because it offers convenient 3-day dosing. The convenience does not outweigh the resistance concerns and inferior microbiologic coverage for the primary pathogens (S. pneumoniae and H. influenzae) causing acute bacterial sinusitis.
Special Circumstance: Chronic Rhinosinusitis
For refractory chronic rhinosinusitis (not acute sinusitis), low-dose azithromycin (250 mg three times weekly for 3-4 months) may have a role through anti-inflammatory mechanisms 9, 10. However, evidence is mixed 11, and the 2025 adult sinusitis guideline 12 notes no clear evidence demonstrating benefit from routine antibiotic use in chronic rhinosinusitis. This is a completely different clinical scenario from acute bacterial sinusitis.
Bottom Line
Use amoxicillin or amoxicillin-clavulanate for acute bacterial sinusitis. Reserve azithromycin only for true penicillin allergy situations where cephalosporins are also contraindicated, and even then, recognize you are using a suboptimal agent with known resistance issues. The 3-day convenience of azithromycin does not justify its use when better options exist.